Riskpilot← Back to searchSign inGet full accessMAJORMED AS
ASActiveOrg 913153227Halvor Torgersens Vei 3, 0778 OsloGeneral medical practice activities · NACE 8621Est. 20141 employees
Revenue 2025
NOK 3,7M
+4% vs 2024
EBITDA margin
19.1%
+15% vs 2024
Equity ratio
40.4%
Financial strength
Net profit 2025
NOK 551K
+15% vs 2024
| Revenue | NOK 3,7M | +4% |
| EBITDA | NOK 706K | +15% |
| Net profit | NOK 551K | +15% |
| Total assets | NOK 1,3M | +12% |
| Equity | NOK 534K | +129% |
| Employees | 1 | — |
Legal name
MAJORMED AS
Org number
913153227
Legal form
Aksjeselskap
NACE code
8621 · General medical practice activities
Founded
31. januar 2014
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Tjenesteyting innen allmennmedisin, vaksiner, reisemedisin, kurs, undervisning, rådgivning, foredragsvirksomhet, organisasjons- og lederutvikling, annen terapi og behandling, kursarrangør, samhandlingsprosjekter for spesialisthelsetjenesten og kommunehelsetjenesten
Address
Halvor Torgersens Vei 3, 0778 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 691 | 2 362 | 3 276 | 3 563 | 3 691 |
| Staff expenses | −536 | −1 648 | −1 991 | −1 887 | −1 928 |
| EBITDA | 513 | −34 | 238 | 615 | 706 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 513 | −34 | 238 | 615 | 706 |
| Net financials | −0 | 0 | 1 | −1 | 0 |
| Profit before tax | 513 | −34 | 240 | 614 | 706 |
| Tax | 113 | −0 | 45 | 135 | 155 |
| Net profit | 400 | −34 | 195 | 479 | 551 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 413 | 778 | 910 | 1 177 | 1 322 |
| Equity | 300 | 266 | 205 | 234 | 534 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 113 | 512 | 705 | 944 | 787 |
| Total debt | 113 | 512 | 705 | 944 | 787 |
EBITDA margin
19.1%
This company
15.8%
Market median
+21% vs market
20212025
Equity ratio
40.4%
This company
38.2%
Market median
+6% vs market
20212025
Return on equity
103.0%
This company
18.4%
Market median
+460% vs market
20212025
Net profit margin
14.9%
This company
8.1%
Market median
+84% vs market
20212025
Asset turnover
2.79×
This company
1.12×
Market median
+149% vs market
20212025
Debt / equity
1.47×
This company
0.62×
Market median
-137% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
PJ Chief Executive Officer | Chief Executive Officer | 2014 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MAJORMED AS 
ALEFE ASBoard members of MAJORMED AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Johan Askim | Chief Executive Officer | 0 companies |
| Øyvind Bjerkreim Strand | Chairman | 0 companies |